Anglais

The data table (n=6 variables) contains information about AREDS participant hospitalizations (e.g. reason, time from randomization, duration, primary ICD9 code) during the entire study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.

19 Formulaires  
  1. StudyEvent: NEI Age-Related Eye Disease Study (AREDS)
    1. Eligibility Criteria
    2. The data table (n=142 variables) contains AMD and cataract phenotype information, medical history and socio-demographic information drawn from several data sets (e.g. enrollment_randomization, amdlensphenotype, followup), plus a unique patient identifier (ID2) for participants with a genetic specimen (to be found only in GENSPECPHENOTYPE and GENSPECFUNDUSLENS [pht000376] tables). Nuclear, cortical and posterior subcapsular opacity information is included for both eyes at baseline and end of study. Other disease information (e.g. diabetes, cancer, angina), medical information (e.g. BMI, blood pressure) and smoking status are also included annually throughout follow-up.
    3. The data table (n=12 variables) contains information about the occurrence of adverse events during the AREDS clinical trial, e.g. type of adverse event, severity, primary ICD9 code, outcome, potential relationship to study drug, timing, and treatment. Data were collected through the clinical trial and for the first 6 months of the natural history follow-up immediately after the clinical trial concluded. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    4. The data table (n=25 variables) contains detailed information about cataract phenotypes (n=23 variables) as well as final AMD phenotype (n=1 variable), and patient ID. Nuclear, cortical and posterior subcapsular opacity information is included for both eyes at baseline and end of study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    5. The data table (n=56 variables) contains information about AREDS participants' dietary intake of alcohol, amino acids, carbohydrates, fiber, poly- and monounsaturated fatty acids, proteins, vitamins and minerals. Participants' glycemic index and glycemic load are also included. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    6. The data table (n=102 variables) contains AREDS treatment assignment, basic socio-demographic characteristics and baseline medical history for AREDS participants. Medical history information includes eye disease information such as AMD Category, visual acuity, and past ophthalmic treatments (e.g. cataract surgery, laser treatment), as well as information about the presence/absence of other diseases (e.g. angina, arthritis, cancer, diabetes, high blood pressure), use of prescribed drugs for disease management (e.g. blood-thinning medications, digoxin, thyroid hormones, insulin), use of over-the-counter drugs (e.g. NSAIDs, antacids), intake of vitamins and minerals, and smoking history. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    7. The data table (n=83 variables) contains information obtained at follow-up visits during the AREDS clinical trial (every six months following randomization), annually in person during the natural history follow-up, and via phone between annual in-person visits. Variables include information about AREDS participants' ophthalmic medical history (e.g. cataract or other eye surgery, laser treatment for AMD, retinal repair, capsulotomy, presence/absence of lens, glaucoma, and visual acuity) and general medical information, including new diagnoses of cancer, heart disease, stroke, and peripheral vascular disease, disease history of angina and high blood pressure, current disease status of diabetes, arthritis, and gout, use of prescribed drugs for disease treatment or management (e.g. blood-thinning medications, digoxin, thyroid hormones, insulin), use of over-the-counter drugs (e.g. NSAIDs, antacids), and smoking behavior. For version 3 release of the study, visual acuity data of the right eye have been added for odd-numbered visits. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    8. The data table (n=49 variables) contains information from AREDS participants' fundus photographs, including presence, type, and extent of drusen, presence/extent of RPE depigmentation, SSR (serous sensory retinal) detachments, subretinal hemorrhages, subretinal fibrosis, and geographic atrophy. In addition, information on photocoagulation (PC) treatment for AMD SRNV is included, as well as AMD Severity Scale Scores and AMD Simple Scale Scores calculated from the fundus data. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    9. The data table (n=62) contains information only for AREDS participants who have a genetic specimen. A unique patient identifier (ID2 field) for these participants (to be found only in GENSPECPHENOTYPE [pht000001.v2.p1] and GENSPECFUNDUSLENS data tables) is included instead of the patient identifier used for data tables with all participants (ID field). Information about fundus and lens characteristics are included as follows - fundus: presence, type, and extent of drusen, presence/extent of RPE depigmentation, SSR (serous sensory retinal) detachments, subretinal hemorrhages, subretinal fibrosis, and geographic atrophy; lens: degree of nuclear sclerosis, cortical and posterior subcapsular opacities, and iris pigmentation. In addition, information on photocoagulation (PC) treatment for AMD is included as well as AMD Severity Scale Scores and AMD Simple Scale Scores calculated from the fundus data.
    10. The data table (n=6 variables) contains information about AREDS participant hospitalizations (e.g. reason, time from randomization, duration, primary ICD9 code) during the entire study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    11. The data table (n=21 variables) contains information from AREDS participants' lens photographs, including degree of nuclear sclerosis, cortical and posterior subcapsular opacities, and iris pigmentation. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    12. The data table (n=7 variables) contains information about AREDS participant deaths (e.g. cause, time from randomization) during the entire study. A search using the National Death Index (NDI) yielded additional deaths not identified during the study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    13. The data table (n=44 variables) contains information about AREDS participants' use (e.g. type, frequency, dose, duration) of non-steroidal anti-inflammatory drugs (e.g. aspirin, ibuprofen, acetaminophen, naproxen). Data were collected at in-clinic visits starting in October 2004. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    14. The data table (n=16 variables) contains information about AREDS participants' general vision status (e.g. general vision score, ocular pain score, VFQ overall score), and its effect on participants' behavior (e.g. near and distant activities, social activities, driving, mental health score) as obtained through the VFQ-25 questionnaire. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    15. Subject - Consent Information
    16. Subject - Sample Mapping (including mapping to Coriell IDs)
    17. The data table (n=2 variables) contains information on subjects' annual exposure to sunlight (hours; April through September).
    18. This dataset provides refractive error values obtained from control subjects of the AREDS study (phs000001.v3.p1) and represents a substudy of AREDS ; data of n=7 new variables are provided in addition to basic sociodemographic data. Subject - consent and subject - sample mapping information is available through phs000001.v3.p1.
    19. This dataset provides refractive error values obtained from control subjects of the AREDS study (phs000001.v3.p1) and represents a substudy of AREDS ; data of n=7 new variables are provided in addition to basic sociodemographic data. Subject - consent and subject - sample mapping information is available through phs000001.v3.p1.
pht000378
Description

pht000378

DUMMY ID NUMBER
Description

ID2

Type de données

string

Alias
UMLS CUI [1,1]
C2348585
REASON (ALL PARTICIPANTS)
Description

REASON

Type de données

text

Alias
UMLS CUI [1,1]
C0566251
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
OTHER REASON DESCRIPTION (ALL PARTICIPANTS)
Description

REASONSP

Type de données

string

Alias
UMLS CUI [1,1]
C0205394
UMLS CUI [1,2]
C0566251
UMLS CUI [1,3]
C0678257
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
PRIMARY ICD9 CODE (ALL PARTICIPANTS)
Description

ICD9COD1

Type de données

float

Alias
UMLS CUI [1,1]
C2598420
UMLS CUI [1,2]
C0205225
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
YEARS FROM RANDOMIZATION TO DATE OF HOSPITALIZATION (ALL PARTICIPANTS)
Description

ADMTIME

Type de données

float

Unités de mesure
  • years
Alias
UMLS CUI [1,1]
C0439234
UMLS CUI [1,2]
C0034656
UMLS CUI [1,3]
C0019993
UMLS CUI [1,4]
C0011008
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
years
DAYS FROM ADMIT DATE TO DISCHARGE DATE (ALL PARTICIPANTS)
Description

HOSPTIME

Type de données

text

Unités de mesure
  • days
Alias
UMLS CUI [1,1]
C0439228
UMLS CUI [1,2]
C0750480
UMLS CUI [1,3]
C1302393
UMLS CUI [1,4]
C2710998
UMLS CUI [2,1]
C0681850
UMLS CUI [2,2]
C0444868
days
Retour au début de la page

Similar models

The data table (n=6 variables) contains information about AREDS participant hospitalizations (e.g. reason, time from randomization, duration, primary ICD9 code) during the entire study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.

19 Formulaires
  1. StudyEvent: NEI Age-Related Eye Disease Study (AREDS)
    1. Eligibility Criteria
    2. The data table (n=142 variables) contains AMD and cataract phenotype information, medical history and socio-demographic information drawn from several data sets (e.g. enrollment_randomization, amdlensphenotype, followup), plus a unique patient identifier (ID2) for participants with a genetic specimen (to be found only in GENSPECPHENOTYPE and GENSPECFUNDUSLENS [pht000376] tables). Nuclear, cortical and posterior subcapsular opacity information is included for both eyes at baseline and end of study. Other disease information (e.g. diabetes, cancer, angina), medical information (e.g. BMI, blood pressure) and smoking status are also included annually throughout follow-up.
    3. The data table (n=12 variables) contains information about the occurrence of adverse events during the AREDS clinical trial, e.g. type of adverse event, severity, primary ICD9 code, outcome, potential relationship to study drug, timing, and treatment. Data were collected through the clinical trial and for the first 6 months of the natural history follow-up immediately after the clinical trial concluded. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    4. The data table (n=25 variables) contains detailed information about cataract phenotypes (n=23 variables) as well as final AMD phenotype (n=1 variable), and patient ID. Nuclear, cortical and posterior subcapsular opacity information is included for both eyes at baseline and end of study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    5. The data table (n=56 variables) contains information about AREDS participants' dietary intake of alcohol, amino acids, carbohydrates, fiber, poly- and monounsaturated fatty acids, proteins, vitamins and minerals. Participants' glycemic index and glycemic load are also included. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    6. The data table (n=102 variables) contains AREDS treatment assignment, basic socio-demographic characteristics and baseline medical history for AREDS participants. Medical history information includes eye disease information such as AMD Category, visual acuity, and past ophthalmic treatments (e.g. cataract surgery, laser treatment), as well as information about the presence/absence of other diseases (e.g. angina, arthritis, cancer, diabetes, high blood pressure), use of prescribed drugs for disease management (e.g. blood-thinning medications, digoxin, thyroid hormones, insulin), use of over-the-counter drugs (e.g. NSAIDs, antacids), intake of vitamins and minerals, and smoking history. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    7. The data table (n=83 variables) contains information obtained at follow-up visits during the AREDS clinical trial (every six months following randomization), annually in person during the natural history follow-up, and via phone between annual in-person visits. Variables include information about AREDS participants' ophthalmic medical history (e.g. cataract or other eye surgery, laser treatment for AMD, retinal repair, capsulotomy, presence/absence of lens, glaucoma, and visual acuity) and general medical information, including new diagnoses of cancer, heart disease, stroke, and peripheral vascular disease, disease history of angina and high blood pressure, current disease status of diabetes, arthritis, and gout, use of prescribed drugs for disease treatment or management (e.g. blood-thinning medications, digoxin, thyroid hormones, insulin), use of over-the-counter drugs (e.g. NSAIDs, antacids), and smoking behavior. For version 3 release of the study, visual acuity data of the right eye have been added for odd-numbered visits. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    8. The data table (n=49 variables) contains information from AREDS participants' fundus photographs, including presence, type, and extent of drusen, presence/extent of RPE depigmentation, SSR (serous sensory retinal) detachments, subretinal hemorrhages, subretinal fibrosis, and geographic atrophy. In addition, information on photocoagulation (PC) treatment for AMD SRNV is included, as well as AMD Severity Scale Scores and AMD Simple Scale Scores calculated from the fundus data. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    9. The data table (n=62) contains information only for AREDS participants who have a genetic specimen. A unique patient identifier (ID2 field) for these participants (to be found only in GENSPECPHENOTYPE [pht000001.v2.p1] and GENSPECFUNDUSLENS data tables) is included instead of the patient identifier used for data tables with all participants (ID field). Information about fundus and lens characteristics are included as follows - fundus: presence, type, and extent of drusen, presence/extent of RPE depigmentation, SSR (serous sensory retinal) detachments, subretinal hemorrhages, subretinal fibrosis, and geographic atrophy; lens: degree of nuclear sclerosis, cortical and posterior subcapsular opacities, and iris pigmentation. In addition, information on photocoagulation (PC) treatment for AMD is included as well as AMD Severity Scale Scores and AMD Simple Scale Scores calculated from the fundus data.
    10. The data table (n=6 variables) contains information about AREDS participant hospitalizations (e.g. reason, time from randomization, duration, primary ICD9 code) during the entire study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    11. The data table (n=21 variables) contains information from AREDS participants' lens photographs, including degree of nuclear sclerosis, cortical and posterior subcapsular opacities, and iris pigmentation. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    12. The data table (n=7 variables) contains information about AREDS participant deaths (e.g. cause, time from randomization) during the entire study. A search using the National Death Index (NDI) yielded additional deaths not identified during the study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    13. The data table (n=44 variables) contains information about AREDS participants' use (e.g. type, frequency, dose, duration) of non-steroidal anti-inflammatory drugs (e.g. aspirin, ibuprofen, acetaminophen, naproxen). Data were collected at in-clinic visits starting in October 2004. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    14. The data table (n=16 variables) contains information about AREDS participants' general vision status (e.g. general vision score, ocular pain score, VFQ overall score), and its effect on participants' behavior (e.g. near and distant activities, social activities, driving, mental health score) as obtained through the VFQ-25 questionnaire. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    15. Subject - Consent Information
    16. Subject - Sample Mapping (including mapping to Coriell IDs)
    17. The data table (n=2 variables) contains information on subjects' annual exposure to sunlight (hours; April through September).
    18. This dataset provides refractive error values obtained from control subjects of the AREDS study (phs000001.v3.p1) and represents a substudy of AREDS ; data of n=7 new variables are provided in addition to basic sociodemographic data. Subject - consent and subject - sample mapping information is available through phs000001.v3.p1.
    19. This dataset provides refractive error values obtained from control subjects of the AREDS study (phs000001.v3.p1) and represents a substudy of AREDS ; data of n=7 new variables are provided in addition to basic sociodemographic data. Subject - consent and subject - sample mapping information is available through phs000001.v3.p1.
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
pht000378
ID2
Item
DUMMY ID NUMBER
string
C2348585 (UMLS CUI [1,1])
Item
REASON (ALL PARTICIPANTS)
text
C0566251 (UMLS CUI [1,1])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
CAUSE
Code List
REASON (ALL PARTICIPANTS)
CL Item
Cardiovascular (1)
C0007222 (UMLS CUI [1,1])
CL Item
Respiratory (2)
C0035204 (UMLS CUI [1,1])
CL Item
Malignancy (3)
C0006826 (UMLS CUI [1,1])
CL Item
Accident (4)
C0000924 (UMLS CUI [1,1])
CL Item
Unknown (5)
C0439673 (UMLS CUI [1,1])
CL Item
Other (6)
C0205394 (UMLS CUI [1,1])
REASONSP
Item
OTHER REASON DESCRIPTION (ALL PARTICIPANTS)
string
C0205394 (UMLS CUI [1,1])
C0566251 (UMLS CUI [1,2])
C0678257 (UMLS CUI [1,3])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
ICD9COD1
Item
PRIMARY ICD9 CODE (ALL PARTICIPANTS)
float
C2598420 (UMLS CUI [1,1])
C0205225 (UMLS CUI [1,2])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
ADMTIME
Item
YEARS FROM RANDOMIZATION TO DATE OF HOSPITALIZATION (ALL PARTICIPANTS)
float
C0439234 (UMLS CUI [1,1])
C0034656 (UMLS CUI [1,2])
C0019993 (UMLS CUI [1,3])
C0011008 (UMLS CUI [1,4])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
HOSPTIME
Item
DAYS FROM ADMIT DATE TO DISCHARGE DATE (ALL PARTICIPANTS)
text
C0439228 (UMLS CUI [1,1])
C0750480 (UMLS CUI [1,2])
C1302393 (UMLS CUI [1,3])
C2710998 (UMLS CUI [1,4])
C0681850 (UMLS CUI [2,1])
C0444868 (UMLS CUI [2,2])
Retour au début de la page